DOT Bars Cannabis Use for Safety Workers Despite Federal Reclassification

The Department of Transportation confirms that commercial pilots, truck drivers, and other safety-sensitive transportation workers remain prohibited from using cannabis, even following the recent federal reclassification from Schedule I to Schedule III. This regulatory stance underscores the complex implementation challenges facing the cannabis industry as federal agencies navigate conflicting policy frameworks.

The DOT's position creates a significant disconnect between medical cannabis access and workplace regulations across critical transportation sectors. While rescheduling represents the most substantial federal cannabis policy shift in decades, safety-sensitive industries continue operating under existing federal workplace drug policies that treat cannabis use as grounds for disqualification, regardless of medical necessity or state-level legalization.

This regulatory gap affects approximately 14 million commercial drivers and hundreds of thousands of aviation professionals nationwide, representing a substantial portion of the potential medical cannabis patient population. The continued prohibition limits market expansion opportunities for cannabis companies targeting medical applications, particularly in pain management and PTSD treatment where transportation workers show high demand.

The transportation sector's stance reflects broader federal agency uncertainty about implementing rescheduling across different regulatory domains. While the DEA's rescheduling decision acknowledges accepted medical use and lower abuse potential, individual agencies maintain discretionary authority over workplace safety standards. This fragmented approach creates compliance challenges for cannabis operators and limits patient access across key demographic segments.

Investors should expect continued regulatory complexity as federal agencies reconcile rescheduling with existing safety frameworks. The transportation industry's position signals that meaningful workplace policy changes will require separate regulatory processes beyond DEA rescheduling, potentially extending the timeline for full federal cannabis normalization and limiting near-term market expansion in safety-sensitive sectors.